Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab

Dermatology

Volumn 217, Issue 4, 2008, Pages 360-361

  Balato, Anna ^a   Balato, Nicola ^a   Patruno, Cataldo ^b   Gallo, Lucia ^a   Ayala, Fabio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Dermatology Clinic   (Italy)

Author keywords

Efalizumab; Leishmaniasis; Psoriasis

Indexed keywords

CIPROFLOXACIN; CYCLOSPORIN A; EFALIZUMAB; ETRETIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN;

ADULT; ANTIMICROBIAL THERAPY; ASTHENIA; BIOLOGICAL THERAPY; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FEVER; HUMAN; LEISHMANIA; LETTER; MALE; PARASITE IDENTIFICATION; PRIORITY JOURNAL; PSORIASIS VULGARIS; TREATMENT DURATION; VISCERAL LEISHMANIASIS;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; DIPTERA; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIA; LEISHMANIASIS, VISCERAL; MALE; PSORIASIS; TREATMENT OUTCOME;

EID: 51849117170     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000156087     Document Type: Letter

References (13)

1. Mannocci A, La Torre G, Chiaradia G, et al: Epidemiology and direct medical costs of human leishmaniasis in Italy. J Prev Med Hyg 2007;48:27-36.
2. Cather JC, Menter A: Efalizumab: continuous therapy for chronic psoriasis. Expert Opin Biol Ther 2005;5:393-403.
3. Leonardi CL, Papp KA, Gordon KB, et al: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425-433.
4. Jordan JK: Efalizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother 2005;39:1476-1482.
5. Raptiva (efalizumab): package insert. San Francisco, Genentech, 2005.
6. Leonardi CL, Toth D, Cather JC, et al: A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006;213:204-214.
7. Santos-Juanes J, Coto-Segura P, Mallo S, Galache C, Soto J: Multiple eruptive dermatofibromas in a patient receiving efalizumab. Dermatology 2008;216:363.
8. Langley RG, Carey WP, Rafal ES, et al: Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005;27:1317-1328.
9. Fabre S, Gibert C, Lechiche C, Dereure J, Jorgensen C, Sany J: Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 2005;23:891-892.
10. Romani-Costa V, Sanchez C, Moya F, Estany C: Visceral leishmaniasis related to infliximab administration. Enferm Infecc Microbiol Clin 2004;22:310.
11. Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C: Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology 2006;45:1446-1448.
12. Bagalas V, Kioumis I, Argyropoulou P, Patakas D: Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 2007;26:1344-1345.
13. Ghosn S, Dahdah MJ, Kibbi AG: Mutilating lupoid leishmaniasis: twelve years to make the diagnosis! Dermatology 2008;216:187-189.